Evoke Pharma, Inc. (NASDAQ:EVOK) Short Interest Update

Evoke Pharma, Inc. (NASDAQ:EVOKGet Free Report) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 31,200 shares, a drop of 28.9% from the February 13th total of 43,900 shares. Based on an average daily volume of 18,400 shares, the days-to-cover ratio is presently 1.7 days. Currently, 2.2% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Separately, StockNews.com assumed coverage on shares of Evoke Pharma in a report on Wednesday, March 12th. They issued a “sell” rating for the company.

Get Our Latest Report on EVOK

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. bought a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOKFree Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma at the end of the most recent quarter.

Evoke Pharma Trading Down 10.2 %

Shares of EVOK stock traded down $0.39 on Monday, reaching $3.43. The company’s stock had a trading volume of 48,202 shares, compared to its average volume of 119,644. The stock’s fifty day simple moving average is $4.53 and its 200-day simple moving average is $4.71. Evoke Pharma has a 1 year low of $3.33 and a 1 year high of $12.32. The company has a market capitalization of $5.10 million, a price-to-earnings ratio of -0.31 and a beta of 0.12.

Evoke Pharma (NASDAQ:EVOKGet Free Report) last posted its quarterly earnings data on Thursday, March 13th. The specialty pharmaceutical company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.24). The firm had revenue of $3.31 million for the quarter, compared to analysts’ expectations of $3.08 million. Evoke Pharma had a negative return on equity of 308.49% and a negative net margin of 71.32%.

About Evoke Pharma

(Get Free Report)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.

Featured Articles

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.